To understand the effect of zoledronate and PVP on relieving postoperative residual pain, thoracolumbar arthropathy disorder and recurrent fractures.

A total of 60 patients diagnosed as osteoporotic vertebral compression fracture(OVCF)in Foshan Jianxiang Orthopedics Hospital from July 2020 to July 2021 and concurrent with PVP were enrolled, and the patients with bursting fractures of ather injuries, glucocorticoid history, severe hepaticor renal dysfuction or other diseases were exduded. The patients were divided into the model group (30) and the treatment group (30) according to random numbers table. The model group received vitamin D₂ + calcium tablets for one year; the treatment group received zoledronic acid (once per year)+ vitamin D₂+ calcium tablets for one year. Visual analogue scale, dysfunction scores, incidence of thoracolumbar facet disorder-induced pain, bone density (BMD) and serum bone metabolism indicators were collected and analyzed by repeated measures ANOVA, t test and chi square test.

Compared with the model groups, the differences of visual analogue score(t=2.867, 3.090) and the dysfunction score (t=2.732, 2.277) were all statistically significant at the first three months and one year after treatment(all P<0.05). The incidence of recurrent pain was significantly reduced one year after the treatment compared with the model group (χ²=4.8, P<0.05). BMD of the treatment group improved one year after the treatment compared with the data before treatment (t=-2.723, P<0.05). The inhibition of beta-isomerized C-telopeptide(β-CTX)was statistically significantly compared with the model group at the first three months and one year after the treatment (t=4.687, 2.952, both P<0.05). There was no statistically significant promotion of procollagen I N-terminal propeptide (PINP) and 2, 5(OH)VitD when compared with the model group(both P>0.05). The PINP decreased one year after the treatment (F=5.697, 6.974, both P<0.05), and the treatment group were better than the model group. The β-CTX of the treatment group decreased three months and one year after the treatment compared with the data before the treatment (F=7.036, 5.381, both P<0.05). In the model group, 2, 5 (OH) VitD increased three months after the treatment (F=5.915, P<0.05) and significantly increased one year after the treatment (F=11.690, P<0.01). In the treatment group, 2, 5(OH) VitD increased significantly three months after treatment and one year after the treatment (F=10.354, 11.935, both P<0.01).

Percutaneous vertebroplasty combined with zoledronic acid can significantly improve the pain and dysfunction of elderly patients with osteoporotic lumbar vertebral compression fracture, reduce the incidence of pain induced by thoracolumbar arthropathy disorder, improve bone density, and reduce the risk of vertebral recurrence fracture.